Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E J Sybertz

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|October 23, 1997
In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461M Van Heek, C F France, D S Compton, et al.
Journal of Medicinal Chemistry|July 22, 1994
Mercaptoacyl amino acid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivativesB R Neustadt, E M Smith, T L Nechuta, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|April 1, 1987
Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril)T Baum, R W Watkins, E J Sybertz, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1981
Antihypertensive and hemodynamic actions of SCH 19927, the R,R-isomer and labetalolT Baum, R W Watkins, E J Sybertz, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|April 1, 1987
Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeysE J Sybertz, T Baum, H S Ahn, et al.
Journal of Cardiovascular Pharmacology|December 1, 1996
Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitorS Vemulapalli, R W Watkins, M Chintala, et al.
The Journal of Clinical Investigation|February 1, 1997
Diet-induced obese mice develop peripheral, but not central, resistance to leptinM Van Heek, D S Compton, C F France, et al.
Journal of Medicinal Chemistry|April 1, 1988
Synthesis and pharmacological activity of angiotensin converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolinesE M Smith, G F Swiss, B R Neustadt, et al.
Obesity Research|April 17, 1998
Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese ratsH R Davis, D E Mullins, J M Pines, et al.
Journal of Cardiovascular Pharmacology|July 1, 1983
Angiotensin-converting enzyme inhibitory activity of SCH 31846, a new non-sulfhydryl inhibitorE J Sybertz, T Baum, H S Ahn, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The Journal of Pharmacology and Experimental Therapeutics|October 23, 1997
In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461M Van Heek, C F France, D S Compton, et al.
Journal of Medicinal Chemistry|July 22, 1994
Mercaptoacyl amino acid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivativesB R Neustadt, E M Smith, T L Nechuta, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|April 1, 1987
Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril)T Baum, R W Watkins, E J Sybertz, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1981
Antihypertensive and hemodynamic actions of SCH 19927, the R,R-isomer and labetalolT Baum, R W Watkins, E J Sybertz, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|April 1, 1987
Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeysE J Sybertz, T Baum, H S Ahn, et al.
Journal of Cardiovascular Pharmacology|December 1, 1996
Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitorS Vemulapalli, R W Watkins, M Chintala, et al.
The Journal of Clinical Investigation|February 1, 1997
Diet-induced obese mice develop peripheral, but not central, resistance to leptinM Van Heek, D S Compton, C F France, et al.
Journal of Medicinal Chemistry|April 1, 1988
Synthesis and pharmacological activity of angiotensin converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolinesE M Smith, G F Swiss, B R Neustadt, et al.
Obesity Research|April 17, 1998
Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese ratsH R Davis, D E Mullins, J M Pines, et al.
Journal of Cardiovascular Pharmacology|July 1, 1983
Angiotensin-converting enzyme inhibitory activity of SCH 31846, a new non-sulfhydryl inhibitorE J Sybertz, T Baum, H S Ahn, et al.
Pageof 8